Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370)
South Korea flag South Korea · Delayed Price · Currency is KRW
3,820.00
+180.00 (4.95%)
At close: Jul 31, 2026

Jin Yang Pharmaceutical Balance Sheet

Millions KRW. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
2,7112,2041,7805,118753.5611,720
Short-Term Investments
---2,6007,890120
Trading Asset Securities
3,3493,684233.78877.271,8513,035
Cash & Short-Term Investments
6,0605,8882,0138,59510,49414,875
Cash Growth
43.26%192.43%-76.58%-18.09%-29.45%179.33%
Accounts Receivable
24,36423,06526,09821,71119,88516,670
Other Receivables
50.1680.84399.9976.1163.1442.37
Receivables
24,41423,44526,49821,78820,24817,012
Inventory
14,99115,62214,62317,35315,4239,060
Prepaid Expenses
929.3548.3157.1544.0142.8335.76
Other Current Assets
755.311,021162.97248.99120.0721.97
Total Current Assets
47,15046,02443,35548,02946,32941,005
Property, Plant & Equipment
47,47747,66443,49444,13643,79439,363
Long-Term Investments
3,8721,7741,2433,0874,2794,238
Other Intangible Assets
5,6376,5375,0434,8863,5731,870
Long-Term Accounts Receivable
----0-0
Long-Term Deferred Charges
764.02848.881,1881,6301,407-
Other Long-Term Assets
166,449164,814132,95117,83815,06212,025
Total Assets
271,492267,809227,574119,907114,44498,502

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
3,1253,0284,2062,4442,536265.09
Accrued Expenses
3,2812,5712,5342,5542,2452,061
Short-Term Debt
843.061,1202,7817,52519,53019,822
Current Portion of Long-Term Debt
75,00075,3001,200---
Current Portion of Leases
270.59195.31221.68207.76198.45113.92
Current Income Taxes Payable
--998.771,3741,442678.45
Current Unearned Revenue
145.9779.6413.968.911.9353.21
Other Current Liabilities
8,0455,7847,83810,3984,9744,149
Total Current Liabilities
90,71188,07819,79424,51130,93827,143
Long-Term Debt
--75,300---
Long-Term Leases
257.48141.32179.2498.45253.4676.7
Pension & Post-Retirement Benefits
--620.19431.1302.76-
Long-Term Deferred Tax Liabilities
17,36117,0739,7074,5504,7573,688
Other Long-Term Liabilities
3,1842,6592,0961,5586182,277
Total Liabilities
111,513107,952107,69631,14936,86933,184

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
7,0677,0676,3266,0086,0006,000
Additional Paid-In Capital
23,14223,14213,3669,7379,6259,625
Retained Earnings
109,687109,56688,66661,32351,88440,626
Treasury Stock
---5,643-5,643-5,643-3,069
Comprehensive Income & Other
20,08120,08117,16417,33315,70912,136
Shareholders' Equity
159,978159,857119,87888,75877,57565,318
Total Liabilities & Equity
271,492267,809227,574119,907114,44498,502

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
76,37176,75779,6827,83119,98220,013
Net Cash (Debt)
-70,311-70,869-77,668764.1-9,488-5,138
Net Cash Growth
------
Net Cash Per Share
-5399.22-5690.03-6298.4061.24-705.79-450.13
Filing Date Shares Outstanding
14.1314.1311.4310.7910.7811.18
Total Common Shares Outstanding
14.1314.1311.4310.7910.7811.18
Working Capital
-43,560-42,05423,56123,51815,39113,862
Book Value Per Share
11318.2211309.6210490.958224.037199.145843.71
Tangible Book Value
154,342153,320114,83483,87174,00263,448
Tangible Book Value Per Share
10919.4410847.1510049.587771.286867.595676.41
Land
31,66531,65227,36626,90123,98319,589
Buildings
18,93718,93718,90618,90618,90618,906
Machinery
21,07321,02519,70019,27218,78219,455
Construction In Progress
-17.286.6321,157448.88